This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.
Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder
This guideline covers cardiac rehabilitation and preventing further cardiovascular disease in people aged 18 and over who have had a myocardial infarction. It aims to promote the health of people who have had an MI by encouraging them to attend a cardiac rehabilitation programme and advising them on a healthy lifestyle. It also includes advice on drug therapy.
Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis (IPF) in adults
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)
Evidence-based recommendations on infliximab (Remicade) for acute exacerbations of ulcerative colitis in adults
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B
Evidence-based recommendations on laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (GORD) in adults
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism
This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.
This guidance has been updated and replaced by NICE guideline CG184.
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
This guideline covers people living in England with ancestral links to Bangladesh, India, Nepal, Pakistan or Sri Lanka who use traditional South Asian varieties of smokeless tobacco. The aim is to help them stop using tobacco that is placed in the mouth or nose (but not burned). It does not include oral snuff products that are sucked.
Evidence-based recommendations on high-sensitivity troponin tests for the early rule-out of acute myocardial infarction (AMI)
This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)